Lusutrombopag 3mg tablets

BACKGROUND: Thrombocytopenia represents an obstacle for invasive procedures in chronic liver disease (CLD) patients. We aimed to estimate the appropriate dose and evaluate the efficacy and safety of lusutrombopag for the treatment of thrombocytopenia before percutaneous liver radiofrequency ablation (RFA) for primary hepatic cancer in patients with CLD. METHODS: /µL at screening were randomized to placebo or lusutrombopag 2, 3, or 4 mg once daily for 7 days, followed by a 28-day post-treatment assessment period. The primary efficacy endpoint was the proportion of patients who did not require platelet transfusion before RFA. The pre-specified key secondary efficacy endpoint was the proportion of responders. Adverse events (AEs) and thrombosis-related AEs were evaluated. RESULTS: The proportion of patients who did not require platelet transfusion before RFA and that of responders were significantly higher (p < 0.01) in the 2-mg (80.0, 66.7%), 3-mg (81.3, 68.8%), and 4-mg groups (93.3, 80.0%) compared with the placebo group (20.0, 6.7%) and showed a dose-dependent effect. The incidence of AEs was 97.8 and 100% in the lusutrombopag (all groups) and placebo groups, respectively; no dose-related increase was observed. Four patients experienced thrombosis-related events (one each in the placebo and 2-mg groups, and two in the 4-mg group). A total of 16 (18%) adverse drug reactions occurred in the safety analysis set. CONCLUSIONS: Lusutrombopag 3 mg once daily for 7 days was effective without raising concerns about excessive increases in platelet count. CLINICAL TRIAL REGISTRATION: The study is registered at JapicCTI-121944.

Abstract licence: CC BY 4.0

Lusutrombopag is an oral thrombopoietin receptor agonist (TPO-RA). Clinical trials have shown lusutrombopag’s efficacy in reducing need for preoperative platelet transfusion in patients with chronic liver disease (CLD) and severe thrombocytopenia. This analysis assessed efficacy and safety of lusutrombopag in patients with severe thrombocytopenia and CLD undergoing planned invasive procedures. An electronic database search (through 1 December 2020) identified three randomised, placebo-controlled, double-blind clinical trials comparing lusutrombopag with placebo in patients with CLD and platelet count below 50 × 109/L scheduled to undergo a procedure with a perioperative bleeding risk. A random-effects meta-analysis examined treatment effect, with Cochrane Collaboration’s tool assessing risk of bias. The meta-analysis included 343 (lusutrombopag 3 mg, n = 173; placebo, n = 170) patients. More patients met the criteria for treatment response (platelet count at least 50 × 109/L and increase of at least 20 × 109/L from baseline anytime during the study) with lusutrombopag versus placebo (risk ratio [RR] 6.39; 95% confidence interval [CI] 3.69, 11.07; p < 0.0001). The primary efficacy outcome, proportion of patients requiring no platelet transfusion and no rescue therapy for bleeding for at least 7 days post procedure, was achieved by more patients treated with lusutrombopag versus placebo (RR 3.42; 95% CI 1.86, 6.26; p = 0.0001). The risk of any bleeding event was significantly lower with lusutrombopag compared to placebo (RR 0.55; 95% CI 0.32, 0.95; p = 0.03); conversely, thrombosis event rates were similar between lusutrombopag and placebo (RR 0.79; 95% CI 0.19, 3.24; p = 0.74). This meta-analysis showed that treatment of severe thrombocytopenia with lusutrombopag in patients with CLD prior to a planned invasive procedure was efficacious and safe in increasing platelet counts, avoiding the need for platelet transfusions, and reducing risk of bleeding, thereby enhancing the certainty of evidence supporting the efficacy and safety of lusutrombopag.

Abstract licence: CC BY-NC 4.0

Thrombocytopenia may be associated with increased bleeding risk impacting timing and outcome of invasive procedures in patients with chronic liver disease (CLD). Lusutrombopag, a small‐molecule, thrombopoietin (TPO) receptor agonist, was evaluated as a treatment to raise platelet counts (PCs) in patients with thrombocytopenia and CLD undergoing invasive procedures. L‐PLUS 2 was a global, phase 3, randomized, double‐blind, placebo‐controlled study. Adults with CLD and baseline PCs < 50 × 10 9 /L were randomized to receive once‐daily lusutrombopag 3 mg or placebo ≤ 7 days before an invasive procedure scheduled 2‐7 days after the last dose. The primary endpoint was avoidance of preprocedure platelet transfusion and avoidance of rescue therapy for bleeding. A key secondary endpoint was number of days PCs were ≥ 50 × 10 9 /L throughout the study. Safety analysis was performed on patients who received at least one dose of study drug. This study occurred between June 15, 2015, and April 19, 2017, with a total of 215 randomized patients (lusutrombopag, 108; placebo, 107); 64.8% (70/108) of patients in the lusutrombopag group versus 29.0% (31/107) in the placebo group met the primary endpoint ( P < 0.0001; difference of proportion 95% confidence interval [CI], 36.7 [24.9, 48.5]). The median duration of PCs ≥ 50 × 10 9 /L was 19.2 days with lusutrombopag (without platelet transfusion) compared with 0.0 in the placebo group (with platelet transfusion) ( P = 0.0001). Most adverse events were mild or moderate in severity, and rates were similar in the lusutrombopag and placebo groups (47.7% and 48.6%, respectively). Conclusion: Lusutrombopag was superior to placebo for reducing the need for platelet transfusions and achieved durable PC response in patients with thrombocytopenia and CLD undergoing invasive procedures, with a safety profile similar to placebo.

Abstract licence: CC BY-NC-ND 4.0

Patients with advanced chronic liver disease are characterised by the presence of thrombocytopenia in a proportion ranging from 15% to 84%, depending on the threshold used to define this abnormality and the degree of severity of liver disease.1-3 In these patients, thrombocytopenia is multifactorial and may be associated with an increased risk of bleeding following invasive procedures.4, 5 Indeed, although the platelet count threshold associated with an increased risk of bleeding is debated, current practice guidelines suggest platelet transfusions, or the use of thrombopoietin receptor agonists (TPO-RA), prior to high-risk planned invasive procedures, in patients with chronic liver disease and a platelet count <50 × 109/L.6-9 In this setting, TPO-RA proved to be a solid treatment option to safely and consistently raise platelet counts, thereby significantly decreasing the number of platelet transfusions.9-13 However, from the physician's point of view, avoidance of platelet transfusions may be considered just a proxy for more clinically relevant endpoints, such as the reduction of procedural and post-procedural bleeding.14 Lusutrombopag is an orally available, small-molecule TPO-RA that, in a phase 2b study carried out in patients with severe thrombocytopenia and chronic liver disease undergoing radiofrequency ablation for hepatocellular carcinoma, reduced the proportion of patients needing pre-procedure platelet transfusion relative to placebo (Figure 1 15-17).11 These findings were subsequently replicated in two larger studies that enrolled patients with chronic liver disease and severe thrombocytopenia who were scheduled to undergo various types of planned invasive procedures, and where clinicians were expected to transfuse platelets based on guidelines in order to decrease the likelihood of post-procedural bleeding.11, 13 The results of these trials led to the approval of lusutrombopag in Japan and in the USA for the treatment of thrombocytopenia, and in the EU for severe thrombocytopenia associated with chronic liver disease in patients undergoing an invasive procedure.15, 18, 19 The aim of this secondary analysis of the lusutrombopag studies (phase 2b, L-PLUS 1 and L-PLUS 2) was to evaluate procedural and post-procedural bleeding rates in patients who received lusutrombopag or placebo—and specifically, those who received lusutrombopag without platelet transfusion or placebo with platelet transfusion—so as to explore the potential of a treatment strategy based on TPO-RA administration rather than platelet transfusion in decreasing the rate of bleeding events. This retrospective safety analysis included data pooled from three randomised clinical trials of patients with chronic liver disease and thrombocytopenia undergoing a planned invasive procedure. Patients were randomised to receive 3 mg lusutrombopag or placebo; patients received treatment for up to 7 days and initiated treatment 9-14 days prior to an invasive procedure. If a patient's platelet count was <50 × 109/L no more than 2 days prior to the procedure, a platelet transfusion was mandated. Bleeding-related adverse events that occurred during and after the procedure were summarised descriptively. Additional details are included under Supplementary Materials, Materials and Methods. The pooled analysis included a total of 341 patients (lusutrombopag, n = 171; placebo, n = 170). Of these, 124 (72.5%) patients received lusutrombopag without platelet transfusion, and 126 received placebo with platelet transfusion (74.1%). Patients receiving lusutrombopag without platelet transfusion were split evenly between males (n = 62, 50%) and females (n = 62, 50%); patients receiving placebo with platelet transfusion were prevalently males (n = 81, 64.3%). The mean ages were 60.9 (standard deviation [SD], 11.8) and 61.0 (SD, 12.4) years for patients treated with lusutrombopag without platelet transfusion and placebo with platelet transfusions, respectively. The most common cause of chronic liver disease was hepatitis C (lusutrombopag without platelet transfusion, n = 74, 59.7%; placebo with platelet transfusion, n = 72, 57.1%). The mean baseline platelet counts were well below the 50 × 109/L threshold in both patients who received lusutrombopag without platelet transfusion (41.0 × 109/L) and those who received placebo with platelet transfusion (37.6 × 109/L) (Table S1). Overall, the proportion of patients with procedural and post-procedural bleeding events was numerically higher in the placebo with platelet transfusion group as compared to the lusutrombopag without platelet transfusion group (15/126, 11.9% versus 8/124, 6.5%, Figure 2A), and this result was consistent when bleeding events were considered both during (6/126, 4.8% versus 4/124, 3.2%) and after (9/126, 7.1% versus 5/124, 4.0%) the invasive procedure (Figure 2B). In terms of the main baseline characteristics of patients who experienced a bleeding event, 7 (63.6%) patients were male in the lusutrombopag without platelet transfusion subgroup, compared to 10 (40.0%) in those who received placebo with platelet transfusion; mean age was 65.2 (SD, 13.7) and 70.3 (SD, 11.0) years, respectively. Additional baseline characteristics of patients who experienced a bleeding event are reported in Table S2. For this analysis, procedural and post-procedural bleeding event rates were subdivided according to the type of invasive procedure and by treatment arm. In patients undergoing liver-related invasive procedures, a greater proportion of patients with at least one bleeding event was observed among those who received placebo with platelet transfusion (9/56, 16.1%) as compared to lusutrombopag without platelet transfusion (6/54, 11.1%), while a larger difference was observed in patients undergoing gastrointestinal-related invasive procedures (5/56, 8.9% versus 1/50, 2.0%). These differences were consistent when the bleeding events were considered during (4/56 [7.1%] versus 1/50 [2.0%]) and after (1/56 [1.8%] versus 0) the gastrointestinal-related invasive procedures in patients who received placebo with platelet transfusion as compared to those who received lusutrombopag without platelet transfusion, respectively (Table S3). In this analysis, we included patients who had a platelet count of either <50 × 109/L or ≥50 × 109/L at least once at any time point after the primary invasive procedure, including platelet counts which were the last platelet counts checked prior to the primary invasive procedure. In patients who had a platelet count ≥50 × 109/L, the proportions of procedural bleeding events were similar between patients who received lusutrombopag without platelet transfusion (3.4%) as compared to patients who received placebo with platelet transfusion (3.3%), while the post-procedural bleeding event rate was more than double in the latter group (9.8% versus 4.2%). In contrast, among patients who received placebo with platelet transfusion and who had a platelet count <50 × 109/L after the primary invasive procedure, the event rates were 6.8% and 5.1% for procedural and post-procedural bleeding, respectively (Table S4). The association between bleeding risk and thrombocytopenia in patients with liver disease undergoing procedures has been debated at length, and while some studies have not identified a link between platelet counts and procedural bleeding,20 there is consistent evidence that low platelet count can be considered a risk factor for bleeding in patients undergoing liver biopsy, percutaneous ablation of liver tumours, and several other invasive procedures.4, 6-8, 21-23 In this regard, the most recent consensus conference on coagulation in liver disease stated that platelet count values <50 × 109/L may be associated with higher risk of bleeding, but cautioned that platelet counts alone do not provide a complete characterisation of bleeding event risk.6 Further, both American College of Gastroenterology and American Gastroenterology Association practice guidelines highlight that, in patients with liver disease and thrombocytopenia undergoing invasive procedures, a platelet count ≥50 × 109/L may optimise clot formation and that higher platelet levels may be more appropriate for high-risk procedures, although this may probably require high doses of platelet infusions; therefore, in planned procedures, the use of TPO-RA may be more appropriate.7, 8 Recent studies have shown that the administration of TPO-RA safely and consistently raises platelet counts, obviating the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease undergoing invasive procedures, although it remains to be established whether their use may lead to a decrease in procedural and post-procedural bleeding events.14 The current study reported the results of a secondary analysis of pooled data from three lusutrombopag randomised clinical trials and aimed to explore whether the effects of its administration might be associated with lower rates of procedural and post-procedural bleeding in patients with chronic liver disease and severe thrombocytopenia. In this post hoc analysis, bleeding events in patients who received lusutrombopag without platelet transfusion were compared to those in patients who received placebo with platelet transfusion, considered as the current standard of care, so as to mirror more closely the scenario of the expected use of lusutrombopag in clinical practice. Overall, the results of this exploratory analysis show that the percentage of patients with procedural and post-procedural bleeding events tended to be lower among patients who received lusutrombopag without platelet transfusion as compared to those who received placebo with platelet transfusion (6.5% versus 11.9%). Moreover, this lower tendency of bleeding was observed consistently in both the procedural (3.2% versus 4.8%) and post-procedural (4.0% versus 7.1%) subgroups. This tendency was confirmed in the subgroup of patients undergoing liver-related procedures (11.1% versus 16.1%) and was even more pronounced in patients undergoing gastrointestinal-related (2.0% versus 8.9%) procedures. The present exploratory analysis was not designed to detect statistically significant differences in the rate of bleeding events; while this analysis may be suggestive that there is less occurrence of bleeding events in patients with lusutrombopag versus patients without lusutrombopag as it relates to an invasive procedure, these initial findings need to be confirmed through appropriately designed studies, sufficiently powered to confirm such a treatment benefit. Platelet function may have a role in the observed bleeding events. Platelet function is dependent in part on the quality of platelets being received through the transfusion, the effectiveness of which can be impacted by the age of the platelets being transfused and the quality of the platelets provided from the donor.24-26 Conversely, TPO-RAs lead to endogenous platelet production; however, the functionality of those platelets compared to platelets received through a platelet transfusion has not been studied. Although platelet dysfunction may be a factor in the observed differences of bleeding events, platelet function in patients receiving lusutrombopag as compared to platelet transfusions remains to be investigated. Among patients who achieved a platelet count ≥50 × 109/L at least once at any time point after the primary invasive procedure, patients who received placebo with platelet transfusion had a post-procedural bleeding event rate double that observed in patients treated with lusutrombopag without platelet transfusion (9.8% versus 4.2%). In this regard, it has to be emphasised that due to the timing of data collection, actual platelet count at the time of bleeding was not available, although it could be inferred that platelet count values at the time of the procedure were greater in the lusutrombopag without platelet transfusion subgroup compared to the placebo with platelet transfusion subgroup, as lusutrombopag has been shown to maintain a platelet count greater than 50 × 109/L for approximately three weeks post-administration as compared to the limited magnitude of effect of platelet transfusions.11 All in all, the preliminary results reported here seem to suggest that in this clinical setting, the increase in platelet count determined by the use of lusutrombopag may be associated not only with a significant reduction in the need for platelet transfusions but also with a tendency towards a decreased bleeding rate. This tendency was consistent for patients undergoing liver-related and gastrointestinal procedures and was even more evident following the procedures, and may be explained by the fact that the increase in platelet count induced by lusutrombopag is superior and more persistent than the effect achieved by platelet transfusion, and may therefore induce a greater haemostatic effect.11, 13 Similar to the trend observed in the use of lusutrombopag, the ELEVATE trial reported a decreased rate of bleeding events in the eltrombopag cohort as compared to the placebo cohort (17% and 23%, respectively).9 In the ADAPT 2 trial, the rate of bleeding events in avatrombopag-treated patients as compared to placebo-treated patients was 2.6% versus 4.6%, while in ADAPT 1 the bleeding events were comparable in the two arms (avatrombopag 3.8% versus placebo 3.3%).12, 14 However, comparisons are complicated by the different definition of bleeding events used among studies and by the timing of bleeding events reported. This study has a number of limitations, which are mainly related to the nature of the analyses of trial results. Individually, the clinical studies were not powered to detect a statistically significant difference in bleeding events between study arms, and by comparing the lusutrombopag without platelet transfusion and placebo with platelet transfusion subgroups, these data no longer constitute a randomised population. As this was a post hoc analysis, calculation of P-values was not appropriate for these analyses, and therefore, tests of significance were not included. Additionally, this post hoc analysis is based on bleeding events defined as a safety endpoint, as opposed to an efficacy endpoint. To conclude, these preliminary results infer that the effects of administration of lusutrombopag may be associated with a lower bleeding rate as compared to the standard of care, represented by platelet transfusion, in patients with liver disease and thrombocytopenia undergoing planned invasive procedures, and should be considered thought-provoking while stimulating further research in this patient population. Although we are fully aware of the limitations of the study results, we feel that what we observed may represent a signal that is worth being explored in future clinical trials, or using real-world evidence, so as to confirm these exploratory initial results, and to assess whether the use of TPO-RA may represent not only a safe and valid alternative to platelet transfusions but also a more efficacious and effective treatment option to reduce bleeding events. These studies were funded by Shionogi & Co., Ltd. (Osaka, Japan). EGG is a consultant for Shionogi. TK, TO and RB are employees of Shionogi. PS was an employee of Shionogi at the time of the study. NA is a consultant/advisory board member for Gilead, Echosens, Ligand, Janssen, Shionogi, SpringBank and Trio Healthcare. NA has stock with SpringBank and Allurion and stock options with SpringBank. This study was a collaborative effort of all authors. Medical writing assistance was provided by Meghan Sullivan, PhD, of MedVal Scientific Information Services, LLC (Princeton, NJ, USA), and was funded by Shionogi Inc. (Florham Park, NJ, USA). Phase 2b: M0626 [JapicCTI-121944]; phase 3: L-PLUS 1 [JapicCTI-132323], global L-PLUS 2 study [NCT02389621]. Shionogi Inc has a data sharing policy, and requests can be submitted for anonymised patient-level data. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Abstract licence: CC BY-NC-ND 4.0